The once-monthly drug is still under study but could provide added convenience and another option for patients.

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes,

Key Takeaways One shot a month of an experimental drug yielded promising results in a new clinical trialThe drug, called MariTide, helped patients drop 20% of their weight over a year without hitting a plateauIt's among several new approaches being studied to treat diabetes and obesity WEDNESDAY,